Baseline patient characteristics
| . | No. of patients, N = 869 . | % of patients . | Median (IQR) . |
|---|---|---|---|
| Age, y | 74 (70-78) | ||
| ≤65 | 16 | 2 | |
| 65-74 | 451 | 52 | |
| ≥75 | 402 | 46 | |
| ≥80 | 161 | 19 | |
| Creatinine, mg/dL | 0.98 (0.80-1.22) | ||
| <2 | 802 | 92 | |
| ≥2 | 37 | 5 | |
| Missing | 30 | 3 | |
| ECOG PS | |||
| 0 | 258 | 30 | |
| 1 | 398 | 46 | |
| 2 | 166 | 19 | |
| 3 | 14 | 2 | |
| ISS | |||
| I | 239 | 28 | |
| II | 361 | 42 | |
| III | 269 | 31 | |
| Chromosome abnormalities | |||
| t(4;14) | 80 | 9 | |
| t(14;16) | 22 | 3 | |
| del17p13 | 105 | 12 | |
| Missing | 147 | 17 | |
| Unfavorable profile | 329 | 38 | |
| ADL | 6 (5-6) | ||
| >4 | 750 | 86 | |
| ≤4 | 119 | 14 | |
| IADL | 8 (6-8) | ||
| >5 | 713 | 82 | |
| ≤5 | 156 | 18 | |
| CCI | 0 (0-1) | ||
| ≤1 | 725 | 83 | |
| ≥2 | 144 | 17 | |
| Therapy | |||
| Lenalidomide-containing regimens | 659 | 76 | |
| Proteasome inhibitor-containing regimens | 210 | 24 |
| . | No. of patients, N = 869 . | % of patients . | Median (IQR) . |
|---|---|---|---|
| Age, y | 74 (70-78) | ||
| ≤65 | 16 | 2 | |
| 65-74 | 451 | 52 | |
| ≥75 | 402 | 46 | |
| ≥80 | 161 | 19 | |
| Creatinine, mg/dL | 0.98 (0.80-1.22) | ||
| <2 | 802 | 92 | |
| ≥2 | 37 | 5 | |
| Missing | 30 | 3 | |
| ECOG PS | |||
| 0 | 258 | 30 | |
| 1 | 398 | 46 | |
| 2 | 166 | 19 | |
| 3 | 14 | 2 | |
| ISS | |||
| I | 239 | 28 | |
| II | 361 | 42 | |
| III | 269 | 31 | |
| Chromosome abnormalities | |||
| t(4;14) | 80 | 9 | |
| t(14;16) | 22 | 3 | |
| del17p13 | 105 | 12 | |
| Missing | 147 | 17 | |
| Unfavorable profile | 329 | 38 | |
| ADL | 6 (5-6) | ||
| >4 | 750 | 86 | |
| ≤4 | 119 | 14 | |
| IADL | 8 (6-8) | ||
| >5 | 713 | 82 | |
| ≤5 | 156 | 18 | |
| CCI | 0 (0-1) | ||
| ≤1 | 725 | 83 | |
| ≥2 | 144 | 17 | |
| Therapy | |||
| Lenalidomide-containing regimens | 659 | 76 | |
| Proteasome inhibitor-containing regimens | 210 | 24 |
Unfavorable profile defined as t(4;14) or t(14;16) or del17p13.
ADL, Activity of Daily Living; CCI, Charlson Comorbidity Index; ECOG PS, Eastern Cooperative Oncology Group performance status; IADL, Instrumental Activity of Daily Living; IQR, interquartile range; ISS, International Staging System.